Cosmo flash update: Key products shine - upgraded EBITDA target

Thursday, July 24, 2025 @ 12:00 am

Cosmo reported H1 2025 results, which showed strong growth in its key products, GI Genius and Winlevi, offset by lower sales in Gastro, CDMO & Others, resulting in flat Recurring revenue. FY 2025 guidance is on track, indicating strong growth in H2 2025. The FY 2025 EBITDA target has been increased.

Key catalysts include:

1. Winlevi CHMP re-examination response (Q3 2025)
2. Breezula 6-month topline results phase III AGA trial (early H2 2025)
3. CB-03-10 readout phase Ia trial (H2 2025)

Cosmo Flash Update

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Memo Therapeutics: Phase II trial results from kidney transplant recipients with virus infection

Phase II results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients, with no safety or tolerability concerns observed. Results support progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection.
July 25, 2025

Pharvaris: Topline data of pivotal Phase 3 for angioedema attacks treatment

Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026
July 10, 2025

Cosmo flash update "Building health confidence"

July 8, 2025

RDP Pharma and Singapore's Experimental Drug Development Centre collaborate for inflammation-driven autoimmune diseases

RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.
July 2, 2025

Navignostics' diagnostic technology contributed to improved outcomes in advanced melanoma patients

Navignostics announces the publication of a landmark study in Nature Medicine showing that its single-cell spatial proteomics technology contributed to improved outcomes in advanced melanoma patients, particularly those with no remaining standard treatment options.
June 30, 2025